Yasui-Furukori N - Search Results

1

Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years.

Yasui-Furukori N, Kawamata Y, Sasaki T, Yokoyama S, Okayasu H, Shinozaki M, Takeuchi Y, Sato A, Ishikawa T, Komahashi-Sasaki H, Miyazaki K, Fukasawa T, Furukori H, Sugawara N, Shimoda K. Yasui-Furukori N, et al. Neuropsychiatr Dis Treat. 2023 Apr 17;19:921-928. doi: 10.2147/NDT.S390482. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37089914 Free PMC article.

2

Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.

Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Otani K, Furukori H, Kaneko S, Inoue Y. Suzuki A, et al. Eur Arch Psychiatry Clin Neurosci. 2001;251(2):57-9. doi: 10.1007/s004060170053. Eur Arch Psychiatry Clin Neurosci. 2001. PMID: 11407439 Clinical Trial.

3

The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.

Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, Kaneko S, Inoue Y, Otani K. Suzuki A, et al. Pharmacogenetics. 2001 Aug;11(6):545-50. doi: 10.1097/00008571-200108000-00009. Pharmacogenetics. 2001. PMID: 11505224

4

Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.

Yasui-Furukori N, Kondo T, Ishida M, Furukori H, Suzuki A, Kaneko S, Inoue M, Otani K. Yasui-Furukori N, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):53-7. doi: 10.1016/s0278-5846(01)00218-4. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 11853119 Clinical Trial.

5

Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.

Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, de Vries R, Kaneko S. Ono S, et al. Psychopharmacology (Berl). 2002 Jun;162(1):50-4. doi: 10.1007/s00213-002-1056-8. Epub 2002 Apr 20. Psychopharmacology (Berl). 2002. PMID: 12107617

6

Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.

Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K. Suzuki A, et al. Ther Drug Monit. 2003 Apr;25(2):192-6. doi: 10.1097/00007691-200304000-00008. Ther Drug Monit. 2003. PMID: 12657913 Clinical Trial.

7

Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.

Kato K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K. Kato K, et al. Ther Drug Monit. 2003 Aug;25(4):473-7. doi: 10.1097/00007691-200308000-00010. Ther Drug Monit. 2003. PMID: 12883232 Clinical Trial.

8

Interaction study between fluvoxamine and quazepam.

Kanda H, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Otani K. Kanda H, et al. J Clin Pharmacol. 2003 Dec;43(12):1392-7. doi: 10.1177/0091270003258667. J Clin Pharmacol. 2003. PMID: 14615476 Clinical Trial.

9

Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay.

Yasui-Furukori N, Furukori H, Saito M, Inoue Y, Kaneko S, Tateishi T. Yasui-Furukori N, et al. Ther Drug Monit. 2003 Dec;25(6):709-14. doi: 10.1097/00007691-200312000-00009. Ther Drug Monit. 2003. PMID: 14639057

10

The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil.

Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. Yasui-Furukori N, et al. J Clin Pharmacol. 2004 May;44(5):538-42. doi: 10.1177/0091270004264161. J Clin Pharmacol. 2004. PMID: 15102875

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

377 results

Search Page